Abstract
Objective
To study the risk factors for hemangioma-related complications, treatment indications and analyze the outcome of patients with infantile hemangioma.
Design
Retrospective.
Setting
University hospital.
Patients
Fifty-five patients (1–69 months; median: 12 months) with infantile hemangioma with mean follow-up 19 months. The eligibility was based on the criteria of the International Society for the Study of Vascular Anomalies (ISSVA).
Intervention
The surgical treatment included total excision whereas medical treatment was carried out by interferon and /or corticosteroids.
Main outcome measures
Data was collected including sex, age, prematurity, age at onset, number, anatomic location and size of hemangioma, age at treatment, cause of treatment decision, family history, presence of extra malformations, involvement of internal organs, presence of life altering or life threatening complications, response to treatment, dose and duration of medications, complications associated with treatment, follow-up period, and final outcome.
Results
Thirty-four (62%) patients were followed-up without treatment, whereas 21 others underwent treatment including steroids, interferon, and surgery. The size of hemangioma was a major factor that predicted hemangioma-related complications (P=0.002). Patients with hemangioma related complications had bigger lesions (size ≥40cm2 or the longest size on a single plane ≥5 cm). Nineteen patients (34%) had complications, but only 8 (14.5%) out of them had life or function-threatening complications.
Conclusion
Although dosing and treatment protocol is still debatable, steroids and interferon are good options for hemangioma treatment. The management strategy should be individualized for each case.
Similar content being viewed by others
References
Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, et al. Infantile hemangiomas: current knowledge, future directions. proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol. 2005;22:383–406.
Barrio VR, Drolet BA. Treatment of hemangiomas of infancy. Dermatol Ther. 2005;18:151–159.
Werner JA, Düne AA, Lippert BM, Folz BJ. Optimal treatment of vascular birthmarks. Am J Clin Dermatol. 2003;4:745–756.
Tansg MW, Garzon MC, Freiden IJ. How to measure a growing hemangioma and assess response to therapy. Pediatr Dermatol. 2006;23:187–190.
Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48:477–493.
Pandey A, Gangopadhyay AN, Gopal SC, Kumar V, Sharma SP, Gupta DK, et al. Twenty years’ experience of steroids in infantile hemangioma-a developing country’s perspective. J Pediatr Surg. 2009;44:688–694.
Mulliken JB, MD, Enjolras O. Congenital hemangiomas and infantile hemangioma: Missing links. J Am Acad Dermatol. 2004;50:875–882.
Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, et al. Prospective study of infantile hemangiomas: Clinical charactheristics predicting complications and treatment. J Pediatr. 2006;118:882–887.
Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122:360–367.
Garzon MC, Drolet BA, Baselga E, Chamlin SL, Haggstrom AN, Horii K, et al. Comparison of infantile hemangiomas in preterm and term infants: A prospective study. Arch Dermatol. 2008;144:1231–1232.
Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast Reconstr Surg. 2011;128: 743–752.
Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol. 2001:44:962–972.
Frieden IJ. Which hemangiomas to treat-and how? Arch Dermatol. 1997;133:1593–1595.
Chamlin SL, Haggstrom AN, Drolet BA, Baselge E, Frieden IJ, Garzon MC, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr. 2007;151:684–689.
Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104:1616–1623.
George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140:963–969.
Jiménez-Hernández E, Dueñas-González MT, Quintero-Curiel JL, Velásquez-Ortega J, Magaña-Pérez JA, Berges-García A, et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg. 2008;34:640–647.
Greinwald JH, Burke DK, Bonthius DJ, Bauman NM, Smith RJH. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolayngol Head Neck Surg. 1999:125:21–27.
Dubois J, Hershon L, Carmant L, Belanger S, Leclerc JM, David M. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr. 1999;135:782–785.
Itinteang T, Withers AH, Leadbitter P, Day DJ, Tan ST. Pharmacologic therapies for infantile hemangioma: is there a rational basis? Plast Reconstr Surg. 2011;128:499–507.
Enjolras O, Breviere GM, Roger G, Tovi M, Pellegrino B, Varotti E, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11:99–107.
Zide BM, Levine SM. Hemangioma update: pearls from 30 years of treatment. Ann Plast Surg. 2011 Jul 5. [E-pub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akcay, A., Karakas, Z., Saribeyoglu, E.T. et al. Infantile Hemangiomas: Complications and follow-up. Indian Pediatr 49, 805–809 (2012). https://doi.org/10.1007/s13312-012-0193-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-012-0193-3